background
fingolimod
first
oral
drug
approv
food
drug
administr
treatment
patient
relapsingremit
form
human
demyelin
diseas
multipl
sclerosi
evid
suggest
therapeut
benefit
occur
prevent
egress
lymphocyt
lymph
node
therebi
inhibit
infiltr
diseasecaus
lymphocyt
central
nervou
system
cn
hypothes
treatment
would
affect
lymphocyt
migrat
cn
influenc
diseas
sever
mous
model
viralinduc
neurolog
diseas
method
mice
infect
intracrani
neurotrop
jhm
strain
mous
hepat
viru
infect
anim
treat
increas
dose
mgkg
morbid
mortal
record
infiltr
inflammatori
virusspecif
cell
tetram
stain
cn
mice
determin
use
flow
cytometri
effect
treatment
virusspecif
cell
prolifer
cytokin
product
cytolyt
activ
also
determin
sever
neuroinflamm
demyelin
mice
examin
flow
cytometri
histopatholog
respect
spinal
cord
mice
result
administr
jhmvinfect
mice
result
increas
clinic
diseas
sever
mortal
result
correl
impair
abil
control
viral
replic
p
within
cn
day
postinfect
associ
diminish
accumul
virusspecif
cell
p
cn
reduc
neuroinflamm
mice
correl
increas
retent
lymphocyt
within
drain
cervic
lymph
node
p
treatment
affect
virusspecif
cell
prolifer
express
cytolyt
activ
mice
exhibit
reduct
sever
demyelin
associ
dampen
neuroinflamm
conclus
find
indic
mute
effect
antivir
immun
respons
impact
migrat
accumul
virusspecif
cell
within
cn
acut
viralinduc
encephalomyel
treatment
reduc
sever
neuroinflammatorymedi
demyelin
restrict
access
diseasecaus
lymphocyt
cn
associ
viral
recrudesc
model
multipl
sclerosi
ms
neurodegen
inflammatori
diseas
central
nervou
system
cn
lead
demyelin
progress
neurolog
disabl
also
call
gilenyafingolimod
oral
drug
recent
approv
food
drug
administr
fda
treatment
patient
relapsingremit
form
ms
immunomodulatori
drug
shown
reduc
acut
relaps
also
new
lesion
format
well
disabl
progress
brain
volum
loss
ms
patient
mechan
function
yet
defin
howev
phosphoryl
activ
form
receptor
modul
inhibit
egress
lymphocyt
lymph
node
thought
lead
dampen
autoreact
cell
specif
myelin
antigen
infiltr
cn
importantli
due
lipophil
natur
penetr
bloodbrainbarri
readili
enter
cn
parenchyma
furthermor
detect
situ
suggest
may
influenc
biolog
resid
cell
cn
shown
improv
diseas
sever
experiment
autoimmun
encephalomyel
eae
autoimmun
model
neuroinflamm
demyelin
commonli
use
model
ms
inde
therapeut
administr
eae
model
associ
reduc
neuroinflamm
improv
motor
skill
addit
eae
viral
model
demyelin
also
relev
tool
studi
pathogenesi
neuroinflammatorymedi
demyelin
exampl
infect
suscept
mice
neurotrop
jhm
strain
mous
hepat
viru
jhmv
result
acut
encephalomyel
follow
chronic
demyelin
like
ms
compon
immun
system
cell
macrophag
import
contributor
white
matter
destruct
moreov
jhmvinfect
mice
undergo
chronic
demyelin
show
similar
clinic
histolog
diseas
profil
compar
ms
patient
virus
consid
contribut
caus
ms
jhmv
infect
cn
offer
excel
model
studi
immunopatholog
mechan
drive
demyelin
ms
patient
also
provid
insight
effect
ms
therapeut
within
context
viralinduc
demyelin
evalu
effect
host
defens
diseas
progress
jhmvinfect
mice
find
reveal
treatment
result
increas
mortal
associ
impair
abil
control
viral
replic
alter
antivir
effect
cell
eg
cytokin
secret
cytolyt
activ
affect
lymphocyt
egress
drain
cervic
lymph
node
accumul
virusspecif
cell
within
cn
therefor
treatment
mute
effect
antivir
immun
respons
follow
infect
neurotrop
viru
dampen
traffick
virusspecif
cell
cn
convers
administr
jhmvinfect
mice
reduc
sever
demyelin
limit
infiltr
inflammatori
cell
cn
agematch
week
egfp
knockin
mice
background
mice
anesthet
intraperiton
ip
inject
mixtur
ketamin
western
medic
suppli
arcadia
ca
usa
xylazin
phoenix
pharmaceut
saint
joseph
mo
usa
hank
balanc
salt
solut
mice
inject
intracrani
ic
plaqu
form
unit
pfu
jhmv
strain
suspend
salin
clinic
sever
assess
use
previous
describ
fourpoint
score
scale
ethyl
hydrochlorid
ethyl
mono
dihydrogen
phosphat
ester
purchas
cayman
chemic
co
ann
arbor
mi
usa
administr
vehicl
perform
daili
ip
inject
start
day
postinfect
pi
analysi
viral
titer
mice
sacrif
defin
time
point
one
half
brain
remov
well
spinal
cord
homogen
use
plaqu
assay
perform
use
dbt
mous
astrocytoma
cell
line
experi
anim
studi
review
approv
univers
utah
univers
california
irvin
institut
anim
care
use
committe
immunophenotyp
cellular
infiltr
present
within
cervic
lymph
node
brain
spinal
cord
infect
mice
accomplish
homogen
isol
tissu
gener
singlecel
suspens
analysi
flow
cytometri
previous
describ
brief
isol
cell
fc
block
follow
antibodi
use
immunophenotyp
apcconjug
rat
antimous
b
cell
apcconjug
rat
antimous
cell
peconjug
rat
antimous
apcconjug
rat
antimous
cell
peconjug
rat
antimous
interferongamma
intracellular
cytokin
stain
rat
antimous
apcconjug
rat
antimous
peconjug
rat
antimous
antibodi
secret
cell
tetramerp
viru
specif
cell
tetramerp
virusspecif
cell
cell
isol
intracellular
stain
cultur
supplement
fetal
bovin
serum
lglutamin
penicillinstreptomycin
stimul
ex
vivo
immunodomin
epitop
immunodomin
golgi
stop
h
follow
intracellular
stain
cell
fix
permeabil
use
bd
cytofixcytoperm
plu
kit
stain
intracellular
min
immunophenotyp
lymphocyt
perform
follow
red
blood
cell
lysi
blood
sampl
collect
heparinco
syring
heart
punctur
egfp
knockin
mice
cell
fc
block
stain
peconjug
rat
antimous
sampl
analyz
bd
lsr
ii
flow
cytomet
splenocyt
isol
mice
day
follow
ip
infect
pfu
dm
strain
mous
hepat
viru
mhvdm
enrich
popul
cell
isol
accord
manufactur
instruct
isol
kit
miltenyi
biotec
auburn
ca
usa
label
fluoresc
dye
carboxyfluorescein
diacet
succinimidyl
ester
cfse
life
technolog
grand
island
ny
usa
final
concentr
total
cell
per
well
incub
nm
vehicl
stimul
final
peptid
concentr
cell
immunodomin
epitop
cell
immunodomin
epitop
nonspecif
ova
control
cultur
h
co
complet
media
cell
wash
fc
receptor
block
pb
contain
bsa
dilut
rat
antimous
antibodi
pharmingen
san
jose
ca
usa
next
cell
stain
surfac
antigen
use
apcconjug
rat
antimous
pharmingen
san
jose
ca
usa
accord
viral
peptid
stimul
condit
min
cell
analyz
data
assess
describ
spleenderiv
cell
analyz
lytic
activ
day
follow
ip
infect
mice
pfu
mhvdm
cellenrich
popul
cell
obtain
via
neg
select
use
magnet
label
antibodi
specif
antigen
follow
passag
magnet
column
miltenyi
biotec
auburn
ca
usa
number
cell
determin
tetram
stain
cell
use
effector
popul
rma
cell
murin
lymphoma
cell
line
present
viral
peptid
cytotox
lymphocyt
ctl
cultur
densiti
per
well
flatbottom
format
tissu
cultur
plate
corn
life
scienc
tewksburi
usa
puls
overnight
immunodomin
peptid
specif
mhv
spike
glycoprotein
span
amino
acid
biosynthesi
lewisvil
tx
usa
tcell
expos
either
nm
vehicl
alon
plate
rma
cell
effectortotarget
e
ratio
rang
cocultur
incub
h
co
final
volum
per
well
amount
lactat
dehydrogenas
ldh
releas
lyse
cell
determin
use
cytotox
nonradioact
cytotox
assay
promega
madison
wi
usa
percentag
ctlmediat
lysi
determin
specifi
manufactur
protocol
spleenderiv
cell
mhvdm
infect
mice
analyz
cytokin
secret
cell
isol
describ
use
isol
kit
accord
manufactur
instruct
miltenyi
biotec
auburn
ca
usa
cell
per
well
round
bottom
plate
incub
h
co
presenc
nm
vehicl
supernat
collect
elisa
perform
follow
cytokin
tumor
necrosi
factor
alpha
sampl
run
triplic
accord
manufactur
direct
r
system
minneapoli
mn
usa
clinic
sever
assess
use
previous
describ
fourpoint
score
scale
spinal
cord
isol
defin
time
point
fix
overnight
paraformaldehyd
spinal
cord
separ
coron
section
cryoprotect
sucros
embed
optimum
cut
temperatur
oct
formul
vwr
radnor
pa
usa
next
coron
section
cut
section
stain
luxol
fast
blue
lfb
area
total
white
matter
demyelin
white
matter
determin
imag
j
softwar
demyelin
score
percentag
total
demyelin
along
entir
length
spinal
cord
h
e
stain
perform
determin
extent
inflamm
spinal
cord
section
score
use
fourpoint
scale
assess
neuroinflamm
treatment
jhmvinfect
mice
increas
clinic
diseas
sever
impair
control
viral
replic
egfp
knockin
mice
mice
infect
ic
jhmv
pfu
subsequ
treat
increas
concentr
mgkg
via
ip
inject
administ
daili
start
day
pi
mice
score
daili
day
pi
treatment
result
increas
sever
clinic
diseas
greatest
effect
occur
mgkg
mgkg
dose
p
compar
vehicletr
mice
figur
accord
clinic
data
mice
exhibit
increas
mortal
dosedepend
manner
figur
day
pi
mice
treat
mgkg
surviv
mice
treat
either
mgkg
mgkg
exhibit
approxim
surviv
respect
figur
base
morbid
mortal
data
mgkg
use
subsequ
vivo
studi
treatment
result
increas
viral
burden
within
brain
spinal
cord
determin
plaqu
titer
day
pi
p
compar
vehicletr
control
mice
figur
howev
later
time
pi
major
mice
treat
reduc
viral
titer
level
detect
approxim
pfug
within
brain
spinal
cord
figur
find
indic
increas
mortal
follow
administr
correl
impair
abil
control
viral
replic
within
cn
argu
either
traffick
virusspecif
lymphocyt
impair
andor
antivir
effector
function
neg
affect
cell
antivir
effector
function
treatment
cell
respons
includ
prolifer
secret
ctl
activ
critic
control
jhmv
replic
within
cn
treatment
nm
appreci
effect
dampen
prolifer
either
cell
specif
immunodomin
epitop
spike
glycoprotein
span
amino
acid
residu
cell
recogn
matrix
glycoprotein
peptid
figur
b
lymphocyt
isol
spleen
jhmvdm
infect
mice
day
pi
puls
either
peptid
treat
nm
determin
cytokin
secret
affect
treatment
affect
secret
either
compar
vehicletr
cultur
figur
final
treatment
cell
affect
lytic
activ
compar
control
figur
find
argu
treatment
dampen
antivir
cell
effector
function
next
determin
affect
express
circul
lymphocyt
jhmvinfect
mice
administr
reduc
circul
lymphocyt
p
compar
vehicletr
control
day
pi
figur
b
examin
cell
infiltr
cn
mice
infect
viru
indic
reduc
frequenc
cell
p
day
pi
although
cell
traffick
affect
day
pi
figur
treatment
affect
cell
infiltr
cn
day
pi
figur
e
infiltr
virusspecif
cell
determin
intracellular
stain
respons
treatment
immunodomin
viral
epitop
diminish
day
p
p
follow
treatment
comparison
vehicletr
mice
figur
b
day
pi
infiltr
virusspecif
cell
virusspecif
cell
also
reduc
p
mice
compar
control
anim
figur
infiltr
antibodi
secret
cell
asc
low
cn
jhmvinfect
mice
reduc
either
day
pi
follow
treatment
compar
control
mice
figur
find
indic
administr
neg
impact
recruit
lymphocyt
cn
respons
jhmv
infect
function
antagonist
disrupt
gradient
lymph
node
therebi
trap
lymphocyt
establish
occur
ongo
neuroinflamm
respons
infect
neurotrop
jhmv
drain
cervic
lymph
node
dcln
examin
defin
time
pi
follow
treatment
administr
reveal
increas
size
weight
dcln
mice
compar
control
mice
day
pi
figur
b
immunophenotyp
lymphocyt
dcln
flow
cytometri
reveal
increas
frequenc
b
cell
figur
cell
figur
cell
figur
mice
treat
compar
control
indic
increas
retent
lymphocyt
lymphat
tissu
respons
antagon
investig
potenti
effect
spinal
cord
neuroinflamm
demyelin
jhmvinfect
mice
evalu
sever
white
matter
damag
perform
day
pi
spinal
cord
inflamm
reduc
p
within
spinal
cord
day
pi
assess
h
e
stain
figur
b
moreov
lfb
stain
reveal
signific
p
reduct
demyelin
respons
treatment
compar
control
mice
figur
b
immunophenotyp
infiltr
lymphocyt
spinal
cord
day
pi
reveal
decreas
cell
well
cell
percentag
p
mice
compar
vehicletr
mice
figur
suggest
reduct
sever
demyelin
c
e
b
figur
increas
lymphocyt
retent
dcln
follow
treatment
jhmvinfect
mice
egfp
mice
ic
infect
jhmv
pfu
treat
daili
mgkg
begin
day
pi
day
pi
dcln
isol
examin
size
weight
immunophenotyp
lymphocyt
popul
flow
cytometri
repres
imag
depict
increas
size
dcln
obtain
mice
compar
vehicl
controltr
mice
day
pi
b
averag
weight
dcln
increas
respons
treatment
compar
vehicl
p
treatment
result
increas
retent
b
cell
c
cell
cell
e
defin
time
pi
data
panel
b
e
repres
averag
sem
obtain
two
three
independ
experi
minimum
four
micegroup
p
p
cln
cervic
lymph
node
dcln
drain
cervic
lymph
node
discuss
first
oral
treatment
approv
fda
relaps
form
ms
numer
clinic
trial
highlight
efficaci
demonstr
benefit
relaps
magnet
reson
imag
mri
lesion
addit
disabl
progress
impact
reduct
brain
volum
loss
ms
patient
respons
treatment
although
mechan
exert
protect
effect
defin
gener
accept
main
mode
action
via
immunomodulatori
effect
restrict
lymphocyt
circul
lymph
node
cn
dampen
accumul
activ
lymphocyt
cn
respons
treatment
like
account
reduc
mri
lesion
activ
support
preclin
anim
studi
use
eae
whether
reduct
brain
volum
loss
also
depend
upon
reduc
neuroinflamm
direct
neuroprotect
effect
determin
recent
evid
argu
exert
neuroprotect
effect
anim
receptor
select
ablat
astrocyt
resist
protect
effect
treatment
follow
induct
eae
although
remain
express
circul
lymphocyt
howev
recent
studi
cahalan
et
al
indic
antagon
revers
eae
without
act
express
within
cn
support
notion
restrict
lymphocyt
egress
lymphat
tissu
suffici
diminish
diseas
sever
moreov
mainten
egress
inhibit
requir
efficaci
eae
brain
level
agonist
maintain
steadi
state
full
efficaci
achiev
inhibit
egress
dose
interv
complet
recoveri
circul
lymphocyt
direct
effect
within
cn
demonstr
neuron
astrocyt
bloodbrainbarri
inhibit
migrat
lymphocyt
perivascular
cuff
parenchyma
chose
model
viralinduc
neurolog
diseas
determin
treatment
affect
host
defens
diseas
progress
rational
use
jhmv
model
acut
encephalomyel
demyelin
assess
therapeut
benefit
base
fact
overwhelm
major
preclin
anim
model
examin
mode
action
deriv
eae
yet
drug
affect
model
viralinduc
cn
diseas
well
character
addit
viral
infect
long
thought
role
either
initi
contribut
relaps
ms
patient
treatment
influenc
outcom
respons
viral
infect
highlight
recent
clinic
studi
detail
emerg
herp
zoster
associ
neurolog
complic
ms
patient
treatment
find
suggest
immunosuppress
may
aris
respons
treatment
result
reemerg
persist
virus
howev
administr
mice
infect
lymphocyt
choriomening
amelior
persist
indic
outcom
may
dictat
part
viru
site
infect
relat
observ
studi
demonstr
treatment
agonist
dramat
affect
cytokin
product
diseas
outcom
mice
infect
influenza
viru
indic
immunomodulatori
effect
treatment
regard
viral
model
demyelin
pachner
colleagu
demonstr
administr
effect
clinic
diseas
progress
viral
load
within
cn
use
theiler
murin
encephalomyel
viru
model
demyelin
find
contrast
find
use
eae
treatment
reduc
clinic
diseas
sever
accompani
limit
infiltr
immun
cell
cn
find
show
treatment
jhmvinfect
mice
increas
clinic
diseas
sever
well
mortal
importantli
find
correl
impair
abil
control
viral
replic
within
cn
mute
host
defens
result
receptor
antagon
result
dampen
antivir
cell
effector
respons
eg
prolifer
cytokin
secret
ctl
activ
rather
inabl
lymphocyt
migrat
accumul
within
cn
effect
inde
administr
increas
retent
b
lymphocyt
within
dcln
consist
earlier
report
block
receptor
disrupt
lymphocyt
egress
secondari
lymphat
tissu
although
viral
titer
elev
within
see
figur
previou
page
figur
treatment
reduc
sever
jhmvinduc
demyelin
repres
lfb
h
estain
spinal
cord
imag
show
overal
reduct
sever
inflamm
demyelin
within
white
matter
tract
dash
line
jhmvinfect
egfp
mice
treat
mgkg
compar
vehicl
controltr
mice
day
pi
b
treatment
result
reduc
neuroinflamm
p
demyelin
p
compar
mice
treat
vehicl
control
flow
analysi
spinal
cord
demonstr
reduc
entri
c
cell
infiltr
virusspecif
cell
affect
data
panel
b
repres
two
independ
experi
minimum
ten
micegroup
data
panel
c
present
averag
sem
repres
two
independ
experi
minimum
five
micegroup
p
scale
bar
panel
repres
ssc
side
scatter
cn
mice
surviv
mice
abl
reduc
amount
viru
level
detect
last
day
pi
argu
viral
recrudesc
occur
model
administr
either
prophylact
therapeut
model
eae
result
reduc
lymphocyt
penetr
cn
associ
reduct
sever
demyelin
similarli
result
show
effect
treatment
cn
inflamm
jhmvinfect
mice
correl
reduct
sever
spinal
cord
demyelin
examin
posterior
funiculu
later
white
matter
column
mice
compar
control
show
overal
reduct
lesion
size
demonstr
addit
reduc
myelin
damag
eae
also
effect
limit
spread
demyelin
viral
model
ms
also
shown
prevent
axon
damag
eae
combin
drug
eae
cerebellar
slice
cultur
shown
augment
remyelin
support
regen
potenti
find
support
may
act
directli
upon
resid
cell
cn
promot
protect
repair
support
eleg
studi
chun
colleagu
show
attenu
eae
loss
efficaci
condit
null
mous
mutant
lack
astrocyt
find
highlight
protect
eae
occur
via
nonimmunolog
mechan
suggest
target
signal
within
cn
may
relev
recoveri
eae
ms
patient
whether
extens
axon
spare
andor
remyelin
occur
follow
administr
jhmvinfect
mice
known
time
area
ongo
work
studi
demonstr
mute
effect
antivir
immun
respons
prevent
migrat
accumul
virusspecif
cell
within
cn
acut
viralinduc
encephalomyel
treatment
reduc
sever
neuroinflammatorymedi
demyelin
limit
cell
egress
lymph
node
therebi
reduc
lymphocyt
infiltr
cn
alter
antivir
effect
cell
eg
cytokin
secret
cytolyt
activ
